{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T23:31:10Z","timestamp":1715556670381},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,4,1]]},"DOI":"10.1093\/ndt\/gfl013","type":"journal-article","created":{"date-parts":[[2006,2,14]],"date-time":"2006-02-14T01:33:17Z","timestamp":1139880797000},"page":"846-849","source":"Crossref","is-referenced-by-count":6,"title":["Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering"],"prefix":"10.1093","volume":"21","author":[{"given":"Toshio","family":"Miyata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"van Ypersele de Strihou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2006,2,13]]},"reference":[{"key":"key\n\t\t\t\t20171011051305_BIB1","doi-asserted-by":"crossref","unstructured":"Mogensen CE. Diabetes and hypertension. Lancet1979; 1: 388\u2013389","DOI":"10.1016\/S0140-6736(79)92935-0"},{"key":"key\n\t\t\t\t20171011051305_BIB2","doi-asserted-by":"crossref","unstructured":"Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet1983; 1: 1175\u20131179","DOI":"10.1016\/S0140-6736(83)92462-5"},{"key":"key\n\t\t\t\t20171011051305_BIB3","doi-asserted-by":"crossref","unstructured":"Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med2001; 135: 73\u201387","DOI":"10.7326\/0003-4819-135-2-200107170-00007"},{"key":"key\n\t\t\t\t20171011051305_BIB4","doi-asserted-by":"crossref","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med2001; 345: 851\u2013860","DOI":"10.1056\/NEJMoa011303"},{"key":"key\n\t\t\t\t20171011051305_BIB5","doi-asserted-by":"crossref","unstructured":"Brenner BM, Cooper ME, de Zeeuw D et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med2001; 345: 861\u2013869","DOI":"10.1056\/NEJMoa011161"},{"key":"key\n\t\t\t\t20171011051305_BIB6","doi-asserted-by":"crossref","unstructured":"Parving HH, Lehnert H, Brochner-Mortensen J et al. Irbesartan in patients with type 2 diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med2001; 345: 870\u2013878","DOI":"10.1056\/NEJMoa011489"},{"key":"key\n\t\t\t\t20171011051305_BIB7","doi-asserted-by":"crossref","unstructured":"Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation2002; 106: 672\u2013678","DOI":"10.1161\/01.CIR.0000024416.33113.0A"},{"key":"key\n\t\t\t\t20171011051305_BIB8","doi-asserted-by":"crossref","unstructured":"de Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation2004; 110: 921\u2013927","DOI":"10.1161\/01.CIR.0000139860.33974.28"},{"key":"key\n\t\t\t\t20171011051305_BIB9","doi-asserted-by":"crossref","unstructured":"Weinberg AJ, Zappe DH, Ashton M, Weinberg MS. Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol2004; 24: 340\u2013345","DOI":"10.1159\/000078950"},{"key":"key\n\t\t\t\t20171011051305_BIB10","doi-asserted-by":"crossref","unstructured":"Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. Diabetes Care2003; 26: 150\u2013155","DOI":"10.2337\/diacare.26.1.150"},{"key":"key\n\t\t\t\t20171011051305_BIB11","unstructured":"Tominaga N, Robert A, Izuhara Y et al. Optimal doses of angiotensin receptor type 1 blockers for blood pressure lowering and renoprotection in a type 2 diabetic nephropathy rat model. (submitted)"},{"key":"key\n\t\t\t\t20171011051305_BIB12","doi-asserted-by":"crossref","unstructured":"Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int2005; 67: 799\u2013812","DOI":"10.1111\/j.1523-1755.2005.00145.x"},{"key":"key\n\t\t\t\t20171011051305_BIB13","doi-asserted-by":"crossref","unstructured":"Seikaly MG, Arant BS, Seney FD. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest1990; 86: 1352\u20131357","DOI":"10.1172\/JCI114846"},{"key":"key\n\t\t\t\t20171011051305_BIB14","doi-asserted-by":"crossref","unstructured":"Miyata T, van Ypersele de Strihou C, Ueda Y et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol2002; 13: 2478\u20132487","DOI":"10.1097\/01.ASN.0000032418.67267.F2"},{"key":"key\n\t\t\t\t20171011051305_BIB15","doi-asserted-by":"crossref","unstructured":"Forbes JM, Cooper ME, Thallas V et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes2002; 51: 3274\u20133282","DOI":"10.2337\/diabetes.51.11.3274"},{"key":"key\n\t\t\t\t20171011051305_BIB16","doi-asserted-by":"crossref","unstructured":"Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of \u201ccarbonyl stress\u201d in long-term uremic complications. Kidney Int1999; 55: 389\u2013399","DOI":"10.1046\/j.1523-1755.1999.00302.x"},{"key":"key\n\t\t\t\t20171011051305_BIB17","doi-asserted-by":"crossref","unstructured":"Izuhara Y, Nangaku M, Inagi R et al. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol2005; 16: 3631\u20133641","DOI":"10.1681\/ASN.2005050522"},{"key":"key\n\t\t\t\t20171011051305_BIB18","doi-asserted-by":"crossref","unstructured":"Nangaku M, Miyata T, Sada T et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol2003; 14: 1212\u20131222","DOI":"10.1097\/01.ASN.0000062961.76776.C1"},{"key":"key\n\t\t\t\t20171011051305_BIB19","doi-asserted-by":"crossref","unstructured":"Nangaku M, Izuhara Y, Usuda N et al. In a type 2 diabetic nephropathy rat model, the improvement of obesity by a low calorie diet reduces oxidative\/carbonyl stress and prevents diabetic nephropathy. Nephrol Dial Transplant2005; 20: 2661\u20132669","DOI":"10.1093\/ndt\/gfi096"},{"key":"key\n\t\t\t\t20171011051305_BIB20","doi-asserted-by":"crossref","unstructured":"Horie K, Miyata T, Maeda K et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest1997; 100: 2995\u20133004","DOI":"10.1172\/JCI119853"},{"key":"key\n\t\t\t\t20171011051305_BIB21","doi-asserted-by":"crossref","unstructured":"Monnier VM. Transition metals redox: reviving an old plot for diabetic vascular disease. J Clin Invest2001; 107: 799\u2013801","DOI":"10.1172\/JCI12635"},{"key":"key\n\t\t\t\t20171011051305_BIB22","doi-asserted-by":"crossref","unstructured":"Yan SD, Schmidt AM, Anderson GM et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors\/binding proteins. J Biol Chem1994; 269: 9889\u20139897","DOI":"10.1016\/S0021-9258(17)36966-1"},{"key":"key\n\t\t\t\t20171011051305_BIB23","doi-asserted-by":"crossref","unstructured":"Inagi R, Yamamoto Y, Nangaku M et al. A severe diabetic nephropathy model with early development of nodular-like lesions induced by megsin overexpression in the RAGE\/iNOS transgenic mice. Diabates2006; 55: 1\u201311","DOI":"10.2337\/diabetes.55.02.06.db05-0702"},{"key":"key\n\t\t\t\t20171011051305_BIB24","doi-asserted-by":"crossref","unstructured":"Tanaka T, Miyata T, Inagi R, Fujita T, Nangaku M. Hypoxia in renal disease with proteinuria and\/or glomerular hypertension. Am J Pathol2004; 165: 1979\u20131992","DOI":"10.1016\/S0002-9440(10)63249-X"},{"key":"key\n\t\t\t\t20171011051305_BIB25","doi-asserted-by":"crossref","unstructured":"Shao J, Nangaku M, Miyata T et al. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension2003; 42: 31\u201338","DOI":"10.1161\/01.HYP.0000075082.06183.4E"},{"key":"key\n\t\t\t\t20171011051305_BIB26","doi-asserted-by":"crossref","unstructured":"Nankivell BJ, Boadle RA, Harris DC. Iron accumulation in human chronic renal diseases. Am J Kidney Dis1992; 20: 580\u2013584","DOI":"10.1016\/S0272-6386(12)70222-6"},{"key":"key\n\t\t\t\t20171011051305_BIB27","doi-asserted-by":"crossref","unstructured":"Isizaka N, Aizawa T, Yamazaki L et al. Abnormal iron deposition renal cells in the rat with chronic angiotesin II administration. Lab Invest2002; 82: 87\u201396","DOI":"10.1038\/labinvest.3780398"},{"key":"key\n\t\t\t\t20171011051305_BIB28","doi-asserted-by":"crossref","unstructured":"Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol2002; 283: F209\u2013F220","DOI":"10.1152\/ajprenal.00032.2002"},{"key":"key\n\t\t\t\t20171011051305_BIB29","doi-asserted-by":"crossref","unstructured":"Sola S, Mir MQ, Cheema FA et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation2005; 111: 343\u2013348","DOI":"10.1161\/01.CIR.0000153272.48711.B9"},{"key":"key\n\t\t\t\t20171011051305_BIB30","unstructured":"Izuhara Y, Nangaku M, Shao J et al. A novel inhibitor of advanced glycation: its benefits for renal damage in rat models. (submitted)"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/21\/4\/846\/12881837\/gfl013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T21:35:43Z","timestamp":1627076143000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/21\/4\/846\/1932762\/Renoprotection-of-angiotensin-receptor-blockers"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,13]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2006,2,13]]},"published-print":{"date-parts":[[2006,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfl013","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,4]]},"published":{"date-parts":[[2006,2,13]]}}}